Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Ascorbic acid, together with sodium ascorbate and other salts, creates an osmotic load in the intestinal lumen. This draws water from the surrounding tissues into the gut, increasing fluid volume, softening stool and stimulating peristalsis, which together result in rapid bowel evacuation.

The exact dose and dosing schedule of Moviprep are determined by the prescribing clinician based on the intended procedure, patient weight and renal function. The product is supplied as a powder that must be dissolved in a specified volume of water and consumed according to the prescriber’s instructions.

Safety data for Moviprep in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Moviprep, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Moviprep combines ascorbic acid with electrolytes, offering a lower volume preparation compared with traditional polyethylene‑glycol solutions. It provides rapid cleansing with a taste that many patients find more acceptable, while maintaining comparable efficacy and safety profiles to other approved bowel‑prep regimens.

Store Moviprep at ambient temperature, below 25 °C, in its original sealed container. Protect the powder from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Moviprep is supplied as a powder that must be mixed with a measured amount of water, usually 1 L, according to the label instructions. The solution is then consumed in divided doses as directed by the prescriber, typically within a few hours before the scheduled procedure.

The most serious risks include severe dehydration, significant electrolyte disturbances such as hypokalemia or hyponatremia, acute renal impairment, and rare allergic reactions that may present as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience these symptoms.

Moviprep should be avoided in patients with known hypersensitivity to any of its components, severe renal insufficiency, uncontrolled electrolyte abnormalities, or in those for whom a low‑volume bowel preparation is contraindicated. Pediatric use is not recommended unless specifically prescribed by a specialist.